| Davis, John C |
NCT03412396: Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy |
|
|
| Active, not recruiting | 2 | 50 | US | Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Quality-of-Life Assessment, Quality of Life Assessment, Radical Prostatectomy, Prostatovesiculectomy | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8 | 03/26 | 03/26 | | |
NCT03773471: A Multi-Center Clinical Trial to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making |
|
|
| Completed | N/A | 69 | US | Mobile Health App | Mayo Clinic | Rheumatoid Arthritis | 06/23 | 06/23 | | |
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment |
|
|
| Active, not recruiting | N/A | 150 | US | AtriCure CryoICE & AtriClip LAA Exclusion | AtriCure, Inc. | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 06/24 | 06/26 | | |
| Active, not recruiting | N/A | 1017 | US | Impella 5.5 | Abiomed Inc. | Cardiogenic Shock, Acute Decompensated Heart Failure | 03/25 | 03/25 | | |
| Thaler, Josef |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 07/27 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Recruiting | N/A | 3000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie, Hoffmann-La Roche, Daiichi Sankyo, Pfizer, Novartis, Caris Life Science, AstraZeneca, Seagen Inc., Eli Lilly and Company | Breast Cancer, Breast Carcinoma, Breast Tumor | 06/25 | 06/25 | | |
ABCSG C08, NCT03822572: -Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer |
|
|
| Recruiting | N/A | 788 | Europe | endurance exercise, control | Austrian Breast & Colorectal Cancer Study Group, Oberösterreichische Krebshilfe | Colorectal Carcinoma | 12/26 | 12/26 | | |
| Greil, Richard |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
DIsCOvER, NCT03984214: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 3 | 109 | Europe | Dronabinol in Oral Dosage Form, BX-1, Placebo in Oral Dosage Form | Arbeitsgemeinschaft medikamentoese Tumortherapie, Medical University of Graz, Unidata Geodesign, Bionorica SE | Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic | 09/24 | 09/24 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 01/25 | 11/27 | | |
| Recruiting | 3 | 734 | Europe, Japan, US, RoW | NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy | NovoCure GmbH | Metastatic Non-small Cell Lung Cancer | 10/28 | 10/28 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | zenocutuzumab (MCLA-128), bispecific, MCLA-128 | Merus N.V. | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
TUXEDO-3, NCT05865990: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease |
|
|
| Active, not recruiting | 2 | 63 | Europe | Patritumab deruxtecan, HER3-DXd | MedSIR, Daiichi Sankyo | Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult | 12/25 | 10/26 | | |
LUNAR-4, NCT06558799: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 69 | Europe | NovoTTF-200T, Pembrolizumab | NovoCure GmbH | Non-Small Cell Lung Cancer (NSCLC) | 06/26 | 10/26 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 07/27 | | |
EXPAND, NCT05714345: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy |
|
|
| Active, not recruiting | 2 | 70 | Europe, US | ALLO-647, Fludarabine, Cyclophosphamide, ALLO-501A | Allogene Therapeutics | Relapsed/Refractory Large B Cell Lymphoma | 02/24 | 10/29 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-cel®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |
|
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
|
|
| Recruiting | 2 | 125 | Europe | Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 04/25 | 09/28 | | |
NCT04891809: Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM |
|
|
| Recruiting | 2 | 198 | Europe, RoW | Isatuximab-Irfc 20 MG/ML [Sarclisa], Lenalidomide, Dexamethasone Oral | Arbeitsgemeinschaft medikamentoese Tumortherapie, University of Navarra, Medical University of Vienna, Assign Data Management and Biostatistics GmbH, WiSP GmbH, Sanofi | Newly Diagnosed Multiple Myeloma | 12/27 | 12/28 | | |
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 99 | Europe | Carfilzomib + Ibrutinib, Ibrutinib | Christian Buske, Amgen, Janssen, LP | Waldenstrom Macroglobulinemia | 02/28 | 02/28 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma |
|
|
| Active, not recruiting | 1/2 | 56 | Europe | Sacituzumab govitecan, Trodelvy | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences | Esophagogastric Adenocarcinoma | 02/27 | 03/27 | | |
| Recruiting | 1 | 12 | Europe | APN401 | invIOs GmbH | Advanced Solid Tumor | 03/24 | 03/24 | | |
| Completed | 1 | 15 | Europe, US, RoW | Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 06/24 | 06/24 | | |
NCT01595295: Registry on Hypomethylating Agents in Myeloid Neoplasms |
|
|
| Completed | N/A | 1500 | Europe, RoW | non interventional | Arbeitsgemeinschaft medikamentoese Tumortherapie | Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia | 12/21 | 12/21 | | |
| Recruiting | N/A | 1000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Infectious Disease, COVID-19 | 12/21 | 12/21 | | |
NCT06250465: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry |
|
|
| Recruiting | N/A | 500 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Chronic Lymphocytic Leukemia | 12/27 | 12/27 | | |
NCT03301493: Genomic Testing and Resulting Medical Decisions |
|
|
| Recruiting | N/A | 1000 | Europe | Genomic testing | Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, AstraZeneca | Cancer of Unknown Origin, Cancer Refractory, Cancer of Stomach, Cancer Head Neck, Cancer of Skin, Cancer, Lung, Cancer Colorectal, Cancer of Esophagus, Cancer, Bladder, Cancer, Uterus, Cancer Cervix, Cancer Liver, Cancer, Kidney, Cancer, Breast, Hematologic Neoplasms | 12/24 | 12/24 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
| Recruiting | N/A | 4000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lymphoma | 12/33 | 12/33 | | |
SOUND, NCT05032092: Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer |
|
|
| Recruiting | N/A | 235 | Europe | Next Generation Sequencing, FoundationOne®Liquid CDx, FoundationOne® CDx, Biomarker Monitoring, AVENIO ctDNA Expanded Kit | Medical University of Graz | Locally Advanced Carcinoma, Metastatic Cancer | 07/25 | 06/26 | | |
| Recruiting | N/A | 3000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie, Hoffmann-La Roche, Daiichi Sankyo, Pfizer, Novartis, Caris Life Science, AstraZeneca, Seagen Inc., Eli Lilly and Company | Breast Cancer, Breast Carcinoma, Breast Tumor | 06/25 | 06/25 | | |
ABCSG C08, NCT03822572: -Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer |
|
|
| Recruiting | N/A | 788 | Europe | endurance exercise, control | Austrian Breast & Colorectal Cancer Study Group, Oberösterreichische Krebshilfe | Colorectal Carcinoma | 12/26 | 12/26 | | |
ARIADNE, NCT05326308: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | N/A | 605 | Europe | Zanubrutinib, Brukinsa®, Obinutuzumab, Gazyvaro® | iOMEDICO AG, BeiGene Switzerland GmbH | Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma | 08/28 | 08/28 | | |
| Recruiting | N/A | 3000 | Europe | Non-interventional | Arbeitsgemeinschaft medikamentoese Tumortherapie | Myeloid Diseases | 04/29 | 04/30 | | |
| Recruiting | N/A | 500 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lung Cancer, NSCLC Stage IV, NSCLC, Stage III, SCLC, Extensive Stage, SCLC, Limited Stage | 08/30 | 08/30 | | |
| Liu, Hong |
| Recruiting | 4 | 1428 | RoW | Indomethacin SR, YINDUOMEIXIN, Placebos, sham | Peking Union Medical College Hospital | Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple | 06/28 | 06/30 | | |
NCT04134026: Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients |
|
|
| Not yet recruiting | 4 | 400 | RoW | HIF-PHI, Epoetin Alfa, Epogen | Second Xiangya Hospital of Central South University | Anemia in Incident Dialysis Patients | 10/23 | 10/24 | | |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 12/25 | 12/25 | | |
NCT05173272: Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer |
|
|
| Recruiting | 3 | 286 | RoW | Neoadjuvant Therapy, Neoadjuvant chemotherapy combined with Serplulimab, CCRT, chemoradiation, Brachytherapy | Sichuan Cancer Hospital and Research Institute | Cervical Cancer | 12/27 | 12/28 | | |
NCT04736186: Prevention and Treatment of Pyrrolitinib-associated Diarrhea |
|
|
| Recruiting | 2/3 | 470 | RoW | Loperamide, Loperamide and golden bifid, Loperamide and montmorillonite powder | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 10/22 | 04/23 | | |
NCT04836520: SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. |
|
|
| Completed | 2 | 20 | RoW | SHR6390+anatrozole | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 02/23 | 03/23 | | |
NCT05641506: A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Yangzheng Xiaoji, Niraparib | Sichuan Cancer Hospital and Research Institute | Ovarian Cancer | 10/23 | 05/25 | | |
| Recruiting | 2 | 86 | RoW | Penpulimab, Anlotinib | Sichuan Cancer Hospital and Research Institute | Gynecological Cancer | 12/24 | 12/25 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
NCT06756321: A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy |
|
|
| Recruiting | 1 | 9 | RoW | anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells, Fludarabine, Cyclophosphamide | Affiliated Hospital of Nantong University, Shanghai First Song Biotechnology Co., LTD | Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia | 03/25 | 03/26 | | |
NCT04993794: Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV |
|
|
| Recruiting | N/A | 200 | RoW | XueBiJing Injection, Normal saline | Nanjing Medical University | Cardiovascular Disease, Aortic Dissection, Coronary Artery Disease, Valve Heart Disease, Congenital Heart Disease, Critical Illness | 12/22 | 12/22 | | |
PANDA V, NCT04444349: Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery |
|
|
| Recruiting | N/A | 500 | RoW | Coenzyme Q10, ubiquinone, Standard Medical Therapy | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University | Cardiovascular Disease | 12/25 | 12/25 | | |
NTU-CML-001, NCT05152537: FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia |
|
|
| Recruiting | N/A | 15 | RoW | | Affiliated Hospital of Nantong University | Folate, CML, Treatment-free Remission | 06/23 | 12/23 | | |
NCT04216823: Perfusion Index as an Objective Measure for Supraclavicular Brachial Plexus Block in Pediatric Patients |
|
|
| Completed | N/A | 104 | RoW | perfusion index | Tongji Hospital | Supraclavicular Brachial Plexus Block | 06/23 | 06/23 | | |
NCT05686863: Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children |
|
|
| Completed | N/A | 106 | RoW | Remimazolam, Rema, Esketamine, Esket, Propofol, Prop, remifentanil, remifen | Tongji Hospital | Drug Effect | 07/23 | 07/23 | | |
PANDA, NCT04699279: Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery ( III) |
|
|
| Recruiting | N/A | 300 | RoW | Rosuvastatin 10mg | Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University, The Affiliated Hospital of Qingdao University Medical College | Acute Aortic Syndrome, Aortopathy | 12/24 | 12/24 | | |
NCT05487469: Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass |
|
|
| Recruiting | N/A | 200 | RoW | Thymosin Alpha1, Blank Control | Nanjing Medical University | Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy | 12/23 | 12/23 | | |
Panda II, NCT05339529: Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II) |
|
|
| Recruiting | N/A | 330 | RoW | Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-, Blank control | Nanjing Medical University, Beijing Anzhen Hospital, Second Affiliated Hospital of Nanchang University, Qilu Hospital of Shandong University, The First Affiliated Hospital of Guangzhou Medical University, Northern Jiangsu People's Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Kunming Medical University, Nanjing First Hospital, Nanjing Medical University, Shanghai East Hospital,Tongji University School of Medicine, The Seventh Affiliated Hospital of Xinjiang Medical University, Teda International Cardiovascular Hospital, Tianjin, China, First Affiliated Hospital Bengbu Medical College, West China Hospital Affiliated with Sichuan University | Acute Aortic Syndrome, Aortic Dissection Type a | 12/25 | 12/25 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
NCT05881655: Slow Myopia Progression With Different Irradiance Light |
|
|
| Recruiting | N/A | 75 | RoW | Airdoc Red Lighting Device, Repeated Red Light, Low Lever Laser Therapy, Low Intensity Light Therapy, Photobiomodulation Therapy, Seconee, 650nm Red Light, Special Spectacles to Control Myopia, Essilor® Stellest™ Lenses, H.A.L.T lens | Beijing Airdoc Technology Co., Ltd., Shanghai Children's Medical Center | Myopia, Progressive | 05/24 | 12/25 | | |
PANDA VI, NCT06195267: Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Recruiting | N/A | 500 | RoW | Sivelestat, Blank control | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital | Aortic Dissection, Systemic Inflammatory Response Syndrome, Cardiovascular Diseases (CVD) | 12/25 | 12/25 | | |
COSEFDIP, NCT05755659: Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV. |
|
|
| Recruiting | N/A | 3000 | RoW | Fosaprepitant Dimeglumine for Injection, ShanQi®️ | Xijing Hospital | Neoplasms | 10/24 | 12/24 | | |
PANDA, NCT06707350: Protective Effect of RIPC Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery (Panda VII) |
|
|
| Not yet recruiting | N/A | 500 | RoW | Remote ischemic preconditioning (RIPC), sham condition (control group) | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University | Cardiopulmonary Bypass, Cardiovascular Diseases, Inflammatory Response During Cardiac Surgery | 12/25 | 12/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT06723366: Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery |
|
|
| Not yet recruiting | N/A | 120 | RoW | Angong Niuhuang Pill (ANP), Control (Standard treatment) | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, Capital Medicine University | Cardio-pulmonary Bypass, Cardiovascular Surgery, Cerebral Protection, Brain Injury | 12/25 | 12/25 | | |
PANDA, NCT06730802: Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting ( VIII) |
|
|
| Not yet recruiting | N/A | 400 | RoW | PCSK9 inhibitor, Statin | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital | Myocardial Ischaemic Syndrome, Coronary Heart Disease | 12/26 | 12/26 | | |
NCT01932411: Factors Affect Outcomes in Cardiovascular Surgery |
|
|
| Recruiting | N/A | 5000 | US | | University of California, Davis | Coronary Artery Disease, Valvular Diseases, Vascular Diseases | 02/25 | 07/25 | | |
| Recruiting | N/A | 2000 | RoW | Renal replacement therapy | Nanjing Medical University | Acute Kidney Injury, Cardiac Surgery | 12/25 | 12/25 | | |
NCT04398992: Additive Anti-inflammatory Action for Aortopathy & Arteriopathy |
|
|
| Enrolling by invitation | N/A | 10000 | RoW | observation | Nanjing Medical University, Beijing Anzhen Hospital | Acute Aortic Syndrome | 12/40 | 12/40 | | |
| Recruiting | N/A | 500 | RoW | soluble ST2 | Nanjing Medical University | Cardiovascular Disease | 12/25 | 12/25 | | |
PANDA IV, NCT04444362: Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Enrolling by invitation | N/A | 500 | RoW | Intestinal Microbiota Transplant (IMT) Capsules | Nanjing Medical University, Beijing Anzhen Hospital, Shanghai East Hospital of Tongji University, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University | Cardiovascular Disease, Cardiopulmonary Bypass | 12/25 | 12/25 | | |
PANDA, NCT06728605: Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Not yet recruiting | N/A | 400 | RoW | Enhanced External Counterpulsation (EECP), Sham Comparator | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University | Coronary Heart Disease (CHD), Cardio-pulmonary Bypass, Congestive Heart Failure Chronic, Cardiogenic Shock Acute | 12/25 | 12/25 | | |
BEST-BAO, NCT05631847: Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke |
|
|
| Recruiting | N/A | 336 | RoW | Endovascular treatment, Intravenous thrombolysis (Alteplase) | Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital | Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis, Alteplase, Endovascular Treatment | 01/27 | 05/27 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients |
|
|
| Recruiting | N/A | 2000 | RoW | Observational study, no intervention | Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University | Acute Stroke | 10/22 | 10/23 | | |
NCT04970264: A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer |
|
|
| Recruiting | N/A | 2000 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 03/23 | 03/25 | | |
| Recruiting | N/A | 300 | RoW | ECMO | Nanjing Medical University | Cardiogenic Shock, Cardiac Arrest, Heart Failure, Acute Respiratory Failure, Acute Respiratory Distress Syndrome | 12/25 | 12/25 | | |
| Recruiting | N/A | 1000 | RoW | Intra Aortic Balloon Pump | Nanjing Medical University | Acute Coronary Syndrome, Cardiogenic Shock, Coronary Artery Disease, Heart Failure, Left Ventricular Dysfunction, Low Cardiac Output Syndrome, Post-cardiac Surgery | 12/25 | 12/25 | | |
| Dai, Ru-Ping |
NCT06513923: Comparison of Remimazolam and Propofol on Emergence in Elderly Orthopedic Patients Under General Anesthesia |
|
|
| Completed | 4 | 136 | RoW | Remimazolam, Flumazenil, Propofol | Central South University | Hip Fracture | 09/23 | 10/23 | | |
| Liu, Wei |
NCT06288334: Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children |
|
|
| Recruiting | 4 | 80 | RoW | 1-3 Cetirizine Pharmacokinetic samples | Peking University Third Hospital | Allergic Disease, Children | 03/24 | 05/24 | | |
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction |
|
|
| Terminated | 3 | 535 | Europe, Canada, Japan, US, RoW | BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo | Remedy Pharmaceuticals, Inc. | Brain Edema, Stroke, Acute | 08/23 | 08/23 | | |
| Completed | 3 | 514 | US | Argatroban, Eptifibatide, Placebo | Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS) | Acute Ischemic Stroke | 12/23 | 10/24 | | |
| Recruiting | 3 | 700 | US | Apixaban, Eliquis, Aspirin | Yale University, National Institute of Neurological Disorders and Stroke (NINDS) | Intracerebral Hemorrhage, Atrial Fibrillation | 04/27 | 04/27 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma |
|
|
| Not yet recruiting | 3 | 83 | RoW | Nelarabine injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | 12/25 | 05/26 | | |
NCT05545137: Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection |
|
|
| Completed | 3 | 299 | RoW | Pivmecillinam hydrochloride tablets, Selexid®, Fosfomycin Tromethamine Granules, Monurol® | Benova (Tianjin) Innovative medicine Research Co., Ltd. | Uncomplicated Urinary Tract Infection | 02/24 | 02/24 | | |
